Insulin Delivery

Adolescents and young adults with type 1 diabetes who used a next-generation hybrid closed-loop insulin delivery system saw improvements in HbA1c and time-in-range with no increase in hypoglycemia, study data show.

Many people with type 2 diabetes are only on a basal insulin and are more dependent on noninsulin therapies, and with the advent of additional noninsulin options, such as GLP-1 receptor agonists or SGLT2 inhibitors, their outcomes are improving. There is a community out there that feels that insulins are as good as they can be.

Insulet this week announced separate partnerships with Abbott and Dexcom to integrate continuous glucose monitoring technology with its tubeless artificial pancreas system, according to industry press releases.

Medtronic has recalled its 600 series of MiniMed insulin pumps due to a missing or broken retainer ring, which helps to lock the insulin cartridge in place in the pump’s reservoir compartment, according to the FDA.

A follow-on therapy to insulin aspart was shown to be safe and effective for pump use among adults with type 1 diabetes, with no increased incidence of unexplained hypoglycemia when compared with the reference product, according to findings from an open-label crossover study published in Diabetes Technology & Therapeutics.

Patients with type 1 diabetes may be able to avoid hypoglycemia more effectively without an increase in hyperglycemic episodes if they use a mobile closed-loop control system instead of a sensor-augmented pump, according to findings published in Diabetes Care.

The FDA on Monday approved fast-acting insulin aspart 100 U/mL as a mealtime insulin for children with diabetes, according to a press release from Novo Nordisk.

In 2019, Healio readers were interested in advancements in design and regulation of devices and apps that can work alone or together to help manage diabetes. Insurance coverage for diabetes devices and finding the right device for individuals with diabetes remain issues. 

Approximately half of children and young adults with type 1 diabetes who initiated use of a hybrid closed-loop insulin delivery system, also known as an artificial pancreas, were still using the device in auto mode after 6 months, with 30% of youths discontinuing use of the system altogether, according to findings from a real-world study published in Pediatric Diabetes.

The FDA has granted breakthrough device designation to an investigational bionic pancreas system, according to a press release from Beta Bionics.